Re-examination of MAGE-A3 as a T-cell Therapeutic Target

In 2013, an innovative MAGE-A3-directed cancer therapeutic of great potential value was terminated in the clinic because of neurotoxicity. The safety problems were hypothesized to originate from off-target T-cell receptor activity against a closely related MAGE-A12 peptide. A combination of publishe...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Aaron D., Wang, Xueyin, Sandberg, Mark L., Negri, Kathleen R., Wu, Ming L., Toledo Warshaviak, Dora, Gabrelow, Grant B., McElvain, Michele E., Lee, Bella, Daris, Mark E., Xu, Han, Kamb, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Basic Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946352/
https://www.ncbi.nlm.nih.gov/pubmed/33284140
http://dx.doi.org/10.1097/CJI.0000000000000348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946352/
https://www.ncbi.nlm.nih.gov/pubmed/33284140
http://dx.doi.org/10.1097/CJI.0000000000000348

Ejemplares similares